management of ovarian cancer in pregnant woman
TRANSCRIPT
![Page 1: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/1.jpg)
Management of ovarian cancer
in pregnancy
Charuwan M.D.
![Page 2: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/2.jpg)
Outline Epidemiology Clinical manifestation Investigations Tumor marker Extent of surgery Chemotherapy
![Page 3: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/3.jpg)
Epidemiology In population- based hospital registry
series of malignancies during pregnancy:
- breast
- thyroid- cervix- Hodgkin lymphoma
- ovarian cancer
![Page 4: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/4.jpg)
EpidemiologyLifetime risk of developing ovarian
cancer is 1.4 %0.2 – 2 % of pregnancies are
complicated by adnexal mass
1 – 6 % malignancy
![Page 5: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/5.jpg)
- 1991 – 1999 - N: 4,846,505- 9375 ovarian
masses diagnosed during pregnancy - 87 ovarian cancer (0.93%)
- 115 LMP (1.2%)
Leiserowitz GS et al:Gynecol Oncology2006
![Page 6: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/6.jpg)
Review of publications(1958 – 2007 )
- Mean age 33 years (range 23 – 46 yr)
- FIGO stage I: 59 % stage II: 5 % stage III: 26 % stage IV: 10 %
Palmer J et al:BJOG2009
![Page 7: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/7.jpg)
Clinical manifestations- Prior to the use of U/S:
most adnexal mass remained unrecognized until C/S or symptomatic
Retrospective series:8330 C/S
68 incidental adnexal masses > 5 cm1 malignancy
Dede M, et al:Int J Gynecol Cancer 2007
![Page 8: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/8.jpg)
U/S + Cesarean section
Incidental detection of asymptomatic adnexal mass
![Page 9: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/9.jpg)
Clinical manifestation Nonspecific symptoms:
- abdominal or back pain- constipation- abdominal distension- urinary symptoms
Palpable mass from PV Acute abdominal pain: torsion
![Page 10: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/10.jpg)
U/S- Size > 10 cm + tumor growth
rate > 3.5 cm/week :
Risk of malignancy
Yen CF, et al: Risk analysis of torsion and malignancy for adnexal masses during pregnancy, Fertil Steri 2009.
![Page 11: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/11.jpg)
U/SOvarian mass < 5 cm :
benign(follicular cyst or corpus luteal cyst)
The majority of persistent adnexal mass ≥ 5 cm are dermoid
![Page 12: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/12.jpg)
MRI U/S is inconclusive or insufficient
data Fetus does not expose to ionizing
radiation Soft tissue pathology : - peduncutated myoma
degenerated myoma- endometrioma- massive ovarian edema
![Page 13: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/13.jpg)
CT CT pelvis: fetal ionizing radiation dose
0.035 Gy Fetal radiation exposure < 0.05 Gy: ไม่�เพิ่��ม่
abortion, congenital anomalies, growth restriction or perinatal mortality
Possible increase risk of developing childhood cancer.
Iodinated contrast: transient suppression of the fetal thyroid.
![Page 14: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/14.jpg)
DDxMost common are benign: simple
cyst, hemorrhagic cyst, leiomyomaMost common benign complex mass:
dermoid, endometrioma, hydrosalpinx and cystadenoma
Uncommon: hyperreactio luteinalis, theca lutein cyst and luteoma
![Page 15: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/15.jpg)
DDxAbdominal pain:
- torsion or rupture of ovarian neoplasm
- degeneration of leiomyoma
![Page 16: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/16.jpg)
DiagnosisDefinitive diagnosis bypathologic examination
![Page 17: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/17.jpg)
Tumor marker
![Page 18: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/18.jpg)
Tumor marker in pregnancy Several tumor marker are difficult to
interpret in pregnancy. Oncofetal antigen: AFP, CEA, HCG
and CA – 125 Oncofetal antigens are involved in
biological functions associated with fetal development, differentiation and maturation
![Page 19: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/19.jpg)
Tumor marker in pregnancy The levels are normally elevated
during gestation and fluctuate with gestation age.
They may be abnormally elevated due to abnormal placentation or fetal abnormalities(preeclampsia, Down syndrome, open neural tube defect).
![Page 20: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/20.jpg)
CA 125CA 125 can produce by normal tissues including endometrium
May be elevated during early gestation and immediately following delivery
May be helpful between 15 wk – delivery.
CA 125 level: 1,000 – 10,000 Suggest cancer
75 – 150 could be pregnancy or ovarian cancer
![Page 21: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/21.jpg)
![Page 22: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/22.jpg)
Alpha - fetoproteinDuring pregnancy,
- AFP expressed as multiples of median (MoM) because these value are easy to derive, more stable and allow for interlaboratory variation
Abnormal MSAFP > 2 – 2.5 MoM > 9 MoM should concern for germ cell
tumor if absence of fetal abdominal defect or anencephaly
![Page 23: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/23.jpg)
Alpha – fetoprotein
High MSAFP levels(often > 1000 ng/ml)
- EST- Embryonal carcinoma- Mixed tumor
MSAFP < 500 ng/ml : NTD
![Page 24: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/24.jpg)
Lactate dehydrogenaseLDH is not elevated in normal pregnancy
LDH can elevate in severe preeclampsia and HELLP syndrome
LDH is a reliable marker for diagnosis and FU in pregnancy
![Page 25: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/25.jpg)
Inhibin AInhibin A is made in the
developing placenta:
Inhibin A may be measure for screening Down syndrome (average 2 fold higher)
Early pregnancy
Sonographer should evaluate ovaries ifabnormal serum down screening test
![Page 26: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/26.jpg)
Ovarian tumor in pregnancy
![Page 27: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/27.jpg)
![Page 28: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/28.jpg)
Epithelial ovarian tumor 50 % LMP LMP in pregnancy may exhibit
atypical characteristics suggestive of invasive cancer:
- nuclear enlargement- multifocal microinvasion
Informed pathologist + pathologist skill
![Page 29: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/29.jpg)
Germ cell tumor3/4 of germ cell tumor in
pregnancy: dysgeminomaDysgeminoma are bilateral:
10 – 15%, other germ cell tumor are almost always unilateral
![Page 30: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/30.jpg)
Sex cord- stromal tumors50% granulosa cell tumor1/3 sertoli leydig cell tumorMost of these tumor: unilateral20 % presented with intraperitoneal
hemorrhage and/or hemorrhagic shock
10 – 15 % of stromal tumor secrete androgen and produce virilization
![Page 31: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/31.jpg)
Management
![Page 32: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/32.jpg)
ManagementInterdisciplinary consultation:
- MFM- Gyne -
oncology- Pediatrics- Pathology
![Page 33: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/33.jpg)
I/C for surgeryPersist into second trimesterTumor size > 10 cmSolid or mixed solid and cystic
highly suspicious for malignancy
For early stage and to prevent adnexal torsion, rupture or obstruction of labor
![Page 34: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/34.jpg)
Time to surgery Early second trimester
- Organogenesis is complete: minimizing risk of drug induced teratogenesis- Risk of pregnancy loss is low.- Cystectomy or oophorectomy does not affect progesterone concentration- Almost all functional cyst resolved.- Spontaneous pregnancy losses due to intrinsic fetal abnormalities occur in first trimester
![Page 35: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/35.jpg)
Surgical Approach
![Page 36: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/36.jpg)
Laparoscopy with adnexal mass during pregnancy
Laparoscopy may decrease uterine blood by increasing intraabdominal pressure
- Fetal hypotension, hypoxia
- Uterine perforation by trocar or Veress needle
- Fetal acidosis by CO2 absorption
![Page 37: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/37.jpg)
Surgical approach
Adequate midline incision: minimize need to manipulate gravid uterus
Ascites collection or peritoneal washing
Carefully inspected and palpated contralateral adnexal mass
Preop imaging/intraop. finding suggested benign
Suspected malignancy: frozen sectioncystectomy / USO
![Page 38: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/38.jpg)
Surgical approach- Resection of the contralateral
ovary is not required unless bilateral disease is identified:
This decision must await the frozen section
![Page 39: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/39.jpg)
Surgical approachAll suspicious lesions should be
biopsied.Early stage: considered adequate
surgical stagingAdvance stage: debulking tumor
LMP: adequate surgery
![Page 40: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/40.jpg)
Extent of surgery Clinical judgementBalancing the extent of surgery/expected benefit
It is rare that removal of gravid uterus is required.
Return for secondary cytoreduction following chemotherapy and successful completion of the pregnancy.
![Page 41: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/41.jpg)
Termination of pregnancySome woman diagnosed with ovarian cancer in early pregnancy may choose to undergo TOP.
![Page 42: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/42.jpg)
Early stageT he goal of initial surgery sho
uld be to completely resect all r esidual disease, without disturbi
ng the pregnancy
![Page 43: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/43.jpg)
Early stageChemotherapy
- Stage IA,IB with G2, 3
- Stage IC, II with any grade- Clear cell
![Page 44: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/44.jpg)
Early stage No residual tumor 271 nonpregnant
women:- Cisplatin/observe- Immediate Cisplatin+P32/Cisplatin at the time of
relapseDelay chemotherapyUntil after delivery
No difference of OS
Bolis G: Ann Oncol 1995
![Page 45: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/45.jpg)
Early stageGross residual tumor:
- possibly should not delay chemotherapy > 6 – 8 wks after surgery
![Page 46: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/46.jpg)
Chemotherapy
![Page 47: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/47.jpg)
Chemotherapy during pregnancyRare eventIf indicated: prefer in the second or early third trimester.
![Page 48: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/48.jpg)
Chemotherapy Category D Chemotherapy preferentially kill
rapidly proliferating cells fetus
The risk of spontaneous abortion, fetal death and major malformation depend on drug agent and gestational age.
![Page 49: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/49.jpg)
ChemotherapyFirst 4 wks: all or none phenomenon(either pregnancy loss or no adverse effect)
4 wk – first trimester(organogenesis): risk of fetal malformation
![Page 50: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/50.jpg)
Chemotherapy and breastfeeding
Immune suppressionImpaired growthAssociation with carcinogenesis
American Academy of Pediatrics
![Page 51: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/51.jpg)
Chemotherapy Counselling Immediate/delay chemotherapy Ethical consideration
- patient autonomy- concept of beneficence- nonmalfeasance
Limited data, uncommon clinical problem in pregnancy.Less data on long-term outcomes in offspring
![Page 52: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/52.jpg)
Epithelial ovarian cancerPlatinum and taxane:Limited data
![Page 53: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/53.jpg)
Platinum derivatives during pregnancy Systematic review: 43 pregnancies - 3 IUGR
- 3 Preterm birth- 2 Oligohydramnios- 1 Polyhydramnios
- 1 Ventriculomegaly- 1 Microphthamus
![Page 54: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/54.jpg)
Chemotherapy and breastfeedingEpithelial group:
- Cisplatin is transferred into breast milk (WHO)- Carboplatin: no data- Paclitaxel is lipophilic: potential to be concentrated in breast milk.
![Page 55: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/55.jpg)
TaxaneFew case reports: short term safety but long term outcomes have not been reported.
ICON study: single agent carboplatin
![Page 56: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/56.jpg)
Chemotherapy 217 pregnant women(1983 - 1995)
- congenital abnormalities 18- chromosomal abnormalities 2- still birth 4- spontaneous abortion 15
Multiagent > single agent (25% vs 10%)
![Page 57: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/57.jpg)
Chemotherapy
Second and third trimesterfetal malformation 1.3%IUGRPrematurityLow birth weight
Fetal toxicities: BM suppression, ototoxicity
50 %
![Page 58: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/58.jpg)
Chemotherapy> 35 wks or 3 wks before
delivery: should be avoided- transient myelosuppression- potential bleeding- sepsis- death at the time of delivery
![Page 59: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/59.jpg)
Chemotherapy in EOC Single agent platinum during
pregnancy, followed by PT regimen postpartum.
At least in theory, this approach should be feasible without compromising maternal survival.
![Page 60: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/60.jpg)
Summary of EOC- Surgery :
O ptimal surgical cytoreduction to the e xtent possible consistent with maternal an
d fetal safety. - Chemotherapy is indicated:
- carboplatin during pregnancy
- a fter delivery: PT regimen
![Page 61: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/61.jpg)
Germ cell tumor• Maximal surgical cytoreduction is usually
undertaken initially. • A djuvant chemotherapy is recommended
to reduce the risk of recurrence
S tage IA dysgerminomasS tage I grade I immature teratomas
Except
![Page 62: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/62.jpg)
Germ cell tumorBEP regimenEtoposide: IUGR, neonatal BM
suppression but there are no report of fetal malformations
![Page 63: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/63.jpg)
Germ cell tumor Reports suggest that delaying
chemotherapy increase risk of recurrence.
Chemotherapy should be delayed until afterfirst trimester, but not longer
![Page 64: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/64.jpg)
Chemotherapy and breastfeeding Germ cell tumor: BEP or PVB
- Etoposide is excreted into breastmilk- Cisplatin is C/I by WHO
![Page 65: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/65.jpg)
Summary of Germ cell tumorSurgery:
maximal surgical cytoreduction.
Chemotherapy should be delayed at least until completi
on of the first trimester of pregnancy.
![Page 66: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/66.jpg)
Sex cord stromal tumorSlow progressive.Suggest surgery alone during pregnancy
Chemotherapy can be deferred to postpartum
![Page 67: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/67.jpg)
ChemotherapyReference Cell type GA at
treatChemo
Outcome
Henderson CE,(1993)King LA (1991)Malfetano JH (1990)Tomlinson MW(1997)Malone JM (1986)Kim DS (1989)Metz SA (1989)Weed JC (1979)Hobelt D (1994)
SerousSerousSerousSertoli-LESTESTESTESTEST/Imma
201616242616172320
PCPCPCPCPVBVACVACVACBEP
Preterm(36)Preterm(36)TermE C/S (34)E C/S (32)TermTermPreterm(33)Term
![Page 68: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/68.jpg)
Timing of deliveryEarly delivery to avoid fetal exposure to chemotherapy is reasonable if lung maturity can be documented and GA ≥ 34 wks.
![Page 69: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/69.jpg)
PrognosisNo evidence that pregnancy
worsen prognosis than nonpregnancy matched for histology, stage and grade.
75 % pregnant women are early stage
5 yr survival : 72 – 90 %
![Page 70: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/70.jpg)
Adnexal mass in C/S
• Should be removed: complete surgical removal is preferred over aspiration and cytologic evaluation.
• Frozen section: if available
![Page 71: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/71.jpg)
Summary and recommendations Most adnexal massed in pregnant
women are benign and asymtomatic. Suggested surgery:
- persist into second trimester- > 10 cm - solid or mixed solid-cystic
Multidisciplinary consultation: balancing maternal and fetus risk
![Page 72: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/72.jpg)
Summary and recommendations
Extent of surgery: clinical judgement + balancing the extent of surgery/expected benefit.
When chemotherapy is indicated: started after first trimester and should be avoided 3 wks before delivery
![Page 73: Management of ovarian cancer in pregnant woman](https://reader036.vdocuments.us/reader036/viewer/2022062405/5563ca0ad8b42a054f8b4dc6/html5/thumbnails/73.jpg)
Thank you for your attention